Boshra Louka
Interventional Cardiology · Shreveport, LANPI 1346503307
Payments from drug & device makers
Across 457 payments — averaging $50.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$4K
- Abiomed$3K
- Edwards Lifesciences$2K
- Penumbra, Inc.$2K
- Abbott$2K
- plus $6K from 33 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$5302%
- Travel & lodging$8,27836%
- Food & beverage$14,42562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $4,424 |
| Boston Scientific | 59 | $4,087 |
| Abiomed | 73 | $2,845 |
| Edwards Lifesciences | 17 | $2,328 |
| Penumbra, Inc. | 6 | $1,813 |
| Abbott | 21 | $1,715 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 81 | $1,129 |
| AOP Health US, LLC | 1 | $643 |
| Cardiovascular Systems Inc. | 4 | $601 |
| Shockwave Medical, Inc | 20 | $443 |
| Inari Medical, Inc. | 16 | $330 |
| E.r. Squibb & Sons, L.L.C. | 13 | $251 |
| Endologix LLC | 2 | $247 |
| Recor Medical Inc | 4 | $221 |
| Cvrx, Inc. | 3 | $213 |
| Irhythm Technologies, Inc. | 10 | $202 |
| Stryker | 11 | $193 |
| Terumo Medical Corporation | 1 | $187 |
| Kestra Medical Technology Services, Inc. | 1 | $159 |
| Pfizer | 11 | $156 |
| Novartis | 9 | $146 |
| Johnson & Johnson | 7 | $116 |
| Boehringer Ingelheim | 8 | $116 |
| Sanofi-aventis U.S. LLC | 4 | $99 |
| Amgen | 4 | $64 |
| Merck | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 4 | $60 |
| Philips North America LLC | 3 | $54 |
| Novo Nordisk | 3 | $54 |
| Bayer | 3 | $50 |
| AstraZeneca | 3 | $44 |
| Baxter Healthcare | 2 | $38 |
| Itamar Medical Inc | 3 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Cardiva Medical, Inc. | 1 | $28 |
| Contego Medical, Inc | 2 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,689
- Impella$1,462
- ONYX FRONTIER$1,337
- COREVALVE EVOLUT R$1,330
- Rapiblyk$1,286
- EKOSONIC$1,209
- Mitra Clip system$879
- Edwards SAPIEN 3 Transcatheter Heart Valve$664
- Diamondback Peripheral$444
- AVVIGO Guidance System$277
- FFRangio$216
- TurboHawk$173
- IN.PACT Admiral$163
- Assure WCD$159
- Barostim Neo System$146
- JETi Peripheral Catheter$142
- Paradise Ultrasound Renal Denervation System$142
- ENDOCROSS Device$138
- Torus Stent Graft System$138
- SYMPLICITY G3$131
How this compares
$23,233 in reported general payments places this provider in the 65th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $157,437 |
| JardianceEmpagliflozin | 134 | $117,845 |
| EntrestoSacubitril/Valsartan | 74 | $70,774 |
| XareltoRivaroxaban | 40 | $33,888 |
| BrilintaTicagrelor | 32 | $31,027 |
| Repatha SureclickEvolocumab | 31 | $21,794 |
| FarxigaDapagliflozin Propanediol | 18 | $14,730 |
| OzempicSemaglutide | 12 | $11,170 |
| ClopidogrelClopidogrel Bisulfate | 265 | $3,061 |
| Ranolazine ErRanolazine | 29 | $2,975 |
| Metoprolol Succinate | 226 | $2,714 |
| Rosuvastatin Calcium | 197 | $2,554 |
| Isosorbide Dinitrate | 36 | $2,131 |
| Ezetimibe | 26 | $963 |
| Atorvastatin Calcium | 110 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $156 | $157,437159 claims |
| Boehringer IngelheimJardiance | $116 | $117,845134 claims |
| NovartisEntresto | $146 | $70,77474 claims |
| AstraZenecaBrilinta, Farxiga | $44 | $45,75750 claims |
| Johnson & JohnsonXarelto | $116 | $33,88840 claims |
| Novo NordiskOzempic | $54 | $11,17012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Shreveport
- Steven BaileyShreveport$308K
- Jai VarmaShreveport$186K
- Tarek HelmyShreveport$173K
- James SmithShreveport$45K
- Ray SmithShreveport$45K
- Eric ReevesShreveport$27K
- Pavan KatikaneniShreveport$20K
- George MinaShreveport$19K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.